| Literature DB >> 35335064 |
Ralph Bertram1, Vanessa Bartsch2, Johanna Sodmann2, Luca Hennig2, Engin Müjde2, Jonathan Stock2, Vivienne Ruedig2, Philipp Sodmann3, Daniel Todt4,5, Eike Steinmann4, Wolfgang Hitzl6,7,8, Joerg Steinmann1.
Abstract
In early 2022, the Coronavirus disease 2019 (COVID-19) remains a global challenge. COVID-19 is caused by an increasing number of variants of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Here, we report an outbreak of SARS-CoV-2 breakthrough infections related to a student festive event with 100 mostly vaccinated guests, which took place in Northern Bavaria, Germany, in October 2021. The data were obtained by retrospective guest interviews. In total, 95 students participated in the study, with 94 being fully vaccinated and 24 reporting infection by the delta variant. Correlation analyses among 15 examined variables revealed that time spent at the event, conversation with the supposed index person, and a homologous viral vector vaccination regime were significant risk factors for infection. Non-significant observations related to higher rates of infection included time since last vaccination, shared use of drinking vessels, and number of individual person-to-person contacts at the event. Our data suggest that a high rate of breakthrough infections with the delta variant occurs if no preventive measures are practiced. To limit infection risk, high-quality testing of participants should be considered a mandatory measure at gatherings, irrespective of the participants' vaccination status.Entities:
Keywords: COVID-19; SARS-CoV-2; breakthrough infection; outbreak
Year: 2022 PMID: 35335064 PMCID: PMC8950301 DOI: 10.3390/vaccines10030432
Source DB: PubMed Journal: Vaccines (Basel) ISSN: 2076-393X
Figure 1Floorplan of the venue in which the outbreak took place (only the main room is shown). Numerals represent the following: (1) entry area; (2) seating area; (3) sofa; (4) bar counter; (5) door to the garage. This figure is not drawn to scale.
Study variables and criteria.
| Examined Variables | Risk Factors | Symptoms |
|---|---|---|
| Sex (male/female) | ≥70 years of age | cough, fever (≥38.0 °C) |
| SARS-CoV-2-test before the event | male sex | common cold (blocked/runny nose) |
| COVID-19 symptoms on the day of the event | smoker | headache |
| COVID-19 vaccination status (including date of vaccination and type of vaccine) | (severe) obesity (body mass index > 30 kg/m2) | sore throat |
| Previously diagnosed SARS-CoV-2 infection | cardiovascular diseases | anosmia (loss of smell) or ageusia (loss of taste) |
| Risk factors (see middle margin) | chronic lung diseases | shortness of breath |
| Arrival and departure at the event | chronic kidney and liver diseases | gastrointestinal disorders |
| Contact to assumed index person (<1.5 m distance and >10 min or shorter/more distant conversation) | psychiatric disorders | myalgia |
| Individual contacts to other guests (<1.5 m distance and >10 min) | diabetes mellitus | chest pain |
| Shared use of drinking vessels | cancer | tachycardia |
| SARS-CoV-2 infection after the event (date and type of test) | immune suppression | |
| Symptoms up to 14 days after the event | trisomy 21 | |
| Symptoms 1 month after the event | ||
| Need for hospitalization | ||
| Use and alert of Coronavirus warning app |
Vaccination status of participants.
| Number of Participants | Previous SARS-CoV-2 Infection | 1st | 2nd | 3rd |
|---|---|---|---|---|
| 1 | yes | JNJ | - | - |
| 1 | yes | BNT | - | - |
| 1 | yes | BNT | BNT | - |
| 1 | yes | BNT | BNT | BNT |
| 1 | no | - | - | - |
| 1 | no | JNJ | - | - |
| 10 | no | AZD | AZD | - |
| 26 | no | BNT | BNT | - |
| 3 | no | MOD | MOD | - |
| 44 | no | AZD | BNT | - |
| 1 | no | AZD | MOD | - |
| 1 | no | AZD | BNT | BNT |
| 4 | no | BNT | BNT | BNT |
* AZD, AstraZeneca; BNT, BioNTech/Pfizer; JNJ, Johnson&Johnson; MOD, Moderna.
Selected data for individuals who were infected.
| Individual | Vaccination Status # | Time Since Last Vaccine Dose (d) | Number of Total Contacts | Time at the Event (min) | Type of Contact to Index Person * | Day of First Positive Test after Event | Ag-POCT | PCR (Cycle Threshold) | Number of Symptoms |
|---|---|---|---|---|---|---|---|---|---|
| 1–2 (put. Index) | 2 × BNT | 178 | 12 | 270 | n/a | +1 | pos | pos (24) | 7 |
| 1–6 | 2 × BNT | 136 | 12 | 315 | ++ | +4 | pos | pos (29) | 3 |
| 1–8 | 2 × BNT | 192 | 11 | 255 | ++ | +5 | neg | pos (32) | 7 |
| 1–9 | 2 × BNT | 268 | 18 | 330 | ++ | +2 | pos | neg (36) | 3 |
| 1–10 | 2 × BNT | 112 | 18 | 450 | ++ | +5 | - | pos (19) | 1 |
| 1–11 | 2 × BNT | 154 | 33 | 360 | ++ | +6 | neg | pos (32) | 7 |
| 1–12 | 1 × JNJ | 157 | 19 | 330 | ++ | +6 | neg | pos (32) | 0 |
| 1–13 | 2 × MOD | 143 | 16 | 360 | ++ | +5 | neg | pos (27) | 2 |
| 2–4 | AZD + | 99 | 7 | 330 | - | +4 | pos | pos (20) | 6 |
| 2–5 | AZD + BNT | 141 | 19 | 285 | + | +6 | neg | pos (30) | 8 |
| 2–10 | none | - | 4 | 360 | ++ | +6 | neg | pos (24) | 4 |
| 2–16 | AZD + BNT | 136 | 23 | 300 | ++ | +4 | pos | pos (24) | 4 |
| 2–17 | AZD + BNT | 142 | 50 | 300 | ++ | +4 | pos | pos (20) | 6 |
| 2–24 | 2 × AZD | 156 | 52 | 360 | ++ | +3 | pos | pos (18) | 5 |
| 2–27 | AZD + BNT | 141 | 19 | 360 | ++ | +5 | neg | pos (un-known) | 6 |
| 3–2 | AZD + BNT | 136 | 26 | 345 | - | +5 | - | pos (17) | 7 |
| 3–11 | 2 × AZD | 165 | 20 | 330 | - | +6 | pos | pos (21) | 3 |
| 3–22 | AZD + BNT | 157 | 38 | 510 | - | +7 | neg | pos (30) | 0 |
| 3–26 | AZD + BNT | 127 | 16 | 210 | - | +5 | neg | pos (25) | 5 |
| 3–27 | AZD + BNT | 141 | 11 | 240 | - | +6 | neg | pos (34) | 6 |
| 3–28 | AZD + BNT | 141 | 8 | 240 | - | +6 | pos | pos (24) | 2 |
| 3–30 | AZD + BNT | 141 | 33 | 435 | - | +5 | pos | - | 5 |
| 3–33 | AZD + BNT | 141 | 28 | 390 | - | +6 | neg | pos (un-known) | 7 |
| 3–34 | AZD + BNT | 148 | 25 | 450 | - | +6 | neg | pos (32) | 5 |
# AZD, AstraZeneca; BNT, BioNTech/Pfizer; JNJ, Johnson&Johnson; MOD, Moderna. * n/a: not applicable; ++: closer than 1.5 m (4.9 ft) and for longer than 10 min; +: conversation shorter and/or more distant; -: no direct contact.
Figure 2(a) Schematic overview of interactions between guests at the event (with individual “4-1” exemplary highlighted). Each guest is represented by a node, and all interactions longer than 10 min and with a distance less than 1.5 m are represented as edges between the nodes. The color of the nodes represents test results after the event: red, infection detected; green, no infection detected; dark green, selected individual for representation; grey, unknown. The blue node represents the putative index. An interactive version of the figure is available under URL 1 (Supplementary materials). (b) Contacts between individuals who tested positive after the event (with individual “2-10” exemplary highlighted). An interactive version of the figure is available under URL 2 (Supplementary materials).
Figure 3Histogram of severity of COVID-19 illness with participants who were infected, according to the number of symptoms.
Figure 4(a) Scatter dot plot of the time spent at the event in relation to a positive or negative test. The longer middle lines within the plots represent the median, the shorter lines within the plots bracket the interquartile ranges. Statistical analysis by t-test, two-sided, *** represents p ≤ 0.0002. (b) Calculated risk of infection relative to the duration of stay at the event.